title: Basal calcitonin levels and the response to pentagastrin stimulation in patients after kidney transplantation or on chronic hemodialysis as indicators of medullary carcinoma.
abstract: Plasma concentrations of calcitonin (hCT) were determined in 150 patients with chronic renal failure on chronic hemodialysis therapy (CHD) and in 800 patients after successful kidney transplantation (KT). Basal hCT concentrations exceeded 10 pg/mL in 44 of 150 patients (29%) with CHD and in 48 of 800 (6%) in patients with KT. Among these patients with elevated basal hCT, pentagastrin-stimulated concentrations of hCT exceeded 100 pg/mL in 4 patients with CHD and in 7 with KT. Thyroidectomy was performed in 8 patients (5 with KT, 3 with CHD) revealing the presence of medullary thyroid carcinoma (MTC) (n = 2) or of C-cell hyperplasia (n = 6). Two patients with C-cell hyperplasia had the neoplastic form of this disorder. One patient with MTC and 1 with C-cell hyperplasia also presented a papillary microcarcinoma. Stimulated concentrations of hCT were only moderately elevated in the remaining 3 patients and follow-up rather than surgery was deemed appropriate due to their concomitant severe medical problems. In conclusion, basal concentrations of hCT higher than 10 pg/mL are more common in patients with CHD (29%) and after successful KT (6%) than previously described in patients with thyroid nodular disease (3%). In spite of various additional factors complicating the interpretation of elevated hCT in CHD, pentagastrin-stimulated values above 100 pg/mL must be considered to indicate the presence of C-cell hyperplasia and/or of medullary thyroid carcinoma. Although thyroidectomy would theoretically be the therapy of choice, the potential benefit of the operation must be seen in the context of the patient's general condition.
authors.affiliation: Division of Endocrinology and Metabolism, Institute of Pathology, University of Vienna, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Kotzmann
authors.forename: A
authors.initials: A
authors.lastname: Schmidt
authors.forename: C
authors.initials: C
authors.lastname: Scheuba
authors.forename: K
authors.initials: K
authors.lastname: Kaserer
authors.forename: B
authors.initials: B
authors.lastname: Watschinger
authors.forename: G
authors.initials: G
authors.lastname: Söregi
authors.forename: B
authors.initials: B
authors.lastname: Niederle
authors.forename: H
authors.initials: H
authors.lastname: Vierhapper
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D002116:Calcitonin / Q000097:blood*; D018276:Carcinoma, Medullary / Q000097:blood* / Q000175:diagnosis / Q000209:etiology; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications; D016030:Kidney Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010418:Pentagastrin; D006435:Renal Dialysis / Q000009:adverse effects; D013964:Thyroid Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000209:etiology
chemical_list: D014408:Biomarkers, Tumor; D002116:Calcitonin; D010418:Pentagastrin